OIG: Non-mail order makes up majority of DST claims
By HME News Staff
Updated Fri January 31, 2020
WASHINGTON - Non-mail order claims for diabetes testing supplies made up 85% of the total Medicare market between April 1, 2019, and June 30, 2019, according to a new report from the Office of Inspector General. Suppliers provided 25 brands of testing supplies to Medicare beneficiaries via non-mail order and 21 brands via mail order. The OIG sent documentation requests to 594 non-mail order suppliers and 18 mail-order suppliers to conduct its study. A rule outlined in the Medicare Improvements for Patients and Providers Act (MIPPA) requires providers to make available at least 50% (by volume) of all the types of test strips. Bidding contracts for mail-order diabetes supplies ended Dec. 31, 2018. CMS has not announced when the program will resume.
Comments